ACTARIT

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H11NO3
Molecular Weight	193.1992
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)NC1=CC=C(CC(O)=O)C=C1

InChI

InChIKey=MROJXXOCABQVEF-UHFFFAOYSA-N

InChI=1S/C10H11NO3/c1-7(12)11-9-4-2-8(3-5-9)6-10(13)14/h2-5H,6H2,1H3,(H,11,12)(H,13,14)

HIDE SMILES / InChI

Molecular Formula	C10H11NO3
Molecular Weight	193.1992
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9918236
Curator's Comment: description was created based on several sources, including http://www.clinexprheumatol.org/article.asp?a=1640

Actarit (MS-932) is an anti-inflammatory drug developed in Japan for use in rheumatoid arthritis (RA). Actarit suppresses adjuvant arthritis through modulation of the immune system. Actarit acts on RA synovial cells to reduce cell-cell interactions with autologous synovium infiltrating lymphocytes and to inhibit proinflammatory cytokine and MMP production, leading to amelioration of symptoms of RA.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Rheumatoid arthritis 310 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9918236	Secondary		Approved 8307	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Effect of actarit combination therapy in patients with active rheumatoid arthritis resistant to gold agents].	2001 Jun	11505513
Glucosides of Chaenomeles speciosa remit rat adjuvant arthritis by inhibiting synoviocyte activities.	2003 Nov	14627503
[A case of rheumatoid arthritis/Sjogren's syndrome with acute renal failure due to hyperuricemia associated with mizoribine therapy].	2004 Jun	15291254
[Examination of the escape phenomenon in disease modifying antirheumatic drugs].	2005 Mar	15738628
The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis.	2006	17164995
Photosensitizing properties of Actarit, an antirheumatic drug.	2008	18540480
Inhibitory effect of some acetyl esters and acetamides on glycation of the histone H1.	2008 Jul-Aug	18810996
Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis.	2008 Mar 20	18054182
A new low-field extremity magnetic resonance imaging and proposed compact MRI score: evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis.	2009	19370385
Modeling the solubility of pharmaceuticals in pure solvents and solvent mixtures for drug process design.	2009 Nov	19283772
Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework.	2010 Jun 15	20529913
Determination of actarit from human plasma for bioequivalence studies.	2010 Nov	21969744

Patents

Sample Use Guides

In Vivo Use Guide

300 mg/day, duration of treatment is 24 weeks.

Route of Administration: Oral

In Vitro Use Guide

rheumatoid arthritis primary synovial cells were co-cultured with actarit at 10(-4)-10(-7) M

Substance Class	Chemical Created by `admin` on `Fri Dec 16 17:51:13 UTC 2022` Edited by `admin` on `Fri Dec 16 17:51:13 UTC 2022`
Record UNII	HW5B6351RZ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ACTARIT

Official Name

English

YM-340790

Code

English

ACTARIT [JAN]

Common Name

English

actarit [INN]

Common Name

English

ACTARIT [MART.]

Common Name

English

ACTARIT [MI]

Common Name

English

NSC-170317

Code

English

4-ACETYLAMINOPHENYLACETIC ACID

Systematic Name

English

ORCL

Brand Name

English

(P-ACETAMIDOPHENYL)ACETIC ACID

Common Name

English

MIRABEGRON (M9)

Common Name

English

Actarit [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29634